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Infection by human cytomegalovirus (HCMV) leads to
NKG2C-driven expansion of adaptive natural killer
(NK) cells, contributing to host defense. However,
approximately 4% of all humans carry a homozy-
gous deletion of the gene that encodes NKG2C
(NKG2C/). Assessment of NK cell repertoires in
60 NKG2C/ donors revealed a broad range of NK
cell populations displaying characteristic footprints
of adaptive NK cells, including a terminally differenti-
ated phenotype, functional reprogramming, and
epigenetic remodeling of the interferon (IFN)-g pro-
moter. We found that both NKG2C and NKG2C+
adaptive NK cells expressed high levels of CD2,
which synergistically enhanced ERK and S6RP phos-
phorylation following CD16 ligation. Notably, CD2
co-stimulation was critical for the ability of adaptive
NK cells to respond to antibody-coated target cells.
These results reveal an unexpected redundancy in
the human NK cell response to HCMV and suggest
that CD2 provides ‘‘signal 2’’ in antibody-driven
adaptive NK cell responses.
INTRODUCTION
Human cytomegalovirus (HCMV) is a persistent betaherpes virus
with a worldwide prevalence ranging between 50% and 100% of
the population depending on socioeconomic factors. Congenital1088 Cell Reports 15, 1088–1099, May 3, 2016 ª 2016 The Authors
This is an open access article under the CC BY license (http://creativeHCMV infection is a leading cause of sensorineural hearing loss
in children and a significant cause of neurodevelopmental delay
(Manicklal et al., 2013). Immunocompromised patients with
AIDS, severe combined immunodeficiency (SCID), or those hav-
ing received immunosuppressive treatment in conjunction with
hematopoietic stem cell transplantation (HSCT), frequently
experience life-threatening HCMV infection. Adaptive immunity
plays a crucial role in the control of HCMV (Crough and Khanna,
2009). HCMV-specific T cells have a terminally differentiated
phenotype and can represent up to 40% of the total T cell mem-
ory pool (Sylwester et al., 2005; van Lier et al., 2003).
Natural killer (NK) cells are innate lymphocytes involved in
numerous physiological processes including reproduction (Par-
ham and Moffett, 2013) and immunity to infections (Jost and Alt-
feld, 2013). Recent advances in NK cell biology suggest that NK
cells display adaptive features during CMV infection, contrib-
uting to viral control (Vivier et al., 2011). Unlike T and B cell im-
mune responses, CMV-driven adaptive NK cell responses do
not rely on receptor rearrangement. In mice, infection with
mouse CMV (MCMV) leads to a clonal expansion of NK cells ex-
pressing the activating receptor Ly49H, which binds to the
MCMV-encoded protein m157 (Arase et al., 2002). Optimal dif-
ferentiation of adaptive Ly49H+ NK cells depends on delivery
of ‘‘signal 2,’’ provided through co-stimulation via DNAM-1 (Na-
bekura et al., 2014). The expansion and contraction within the
Ly49H+ NK cell population result in a pool of memory NK cells
that mediate long-lasting protection against subsequent chal-
lenges with the virus (Sun et al., 2009).
In humans, the NK cell response against HCMV results in a
stable imprint of highly differentiated NK cells expressing
DAP12-coupled receptors including NKG2C and activating killercommons.org/licenses/by/4.0/).
AC D E
B Figure 1. Homozygous NKG2C Deletion Is
Associated with Accumulation of Terminally
Differentiated Effector Memory CD45RA+
T Cells
(A and B) Frequency of EMRA CD8 T cells
in HCMV+NKG2C+ donors (A) and HCMV+
NKG2C/ donors (B) plotted against the age of
the donor.
(C) Frequency of EMRA CD8 T cells in donors
<50 and >50 years old as a function of NKG2C
deletion.
(D) Frequency of IFN-g+ CD8 T cells after over-
night stimulation with pp65 overlapping peptide
pools.
(E) Frequency of HCMV-specific CD8 T cells as
defined by HLA-A*02 or HLA-B*07 tetramers re-
folded with pp65-derived peptides. Gray lines
represent the median value within each group.cell immunoglobulin-like receptors (KIRs) (Be´ziat et al., 2013;
Guma´ et al., 2004). Expansion of these NK cell subsets, referred
to as adaptive NK cells, have been observed following HCMV
reactivation in transplanted patients (Della Chiesa et al., 2014;
Foley et al., 2012; Lopez-Verge`s et al., 2011) andwas associated
with viral control in a T–B+NK+ SCID patient experiencing acute
primary HCMV infection (Kuijpers et al., 2008).
Despite accumulating evidence that NKG2C plays a central
role in the NK cell response against HCMV, NKG2C is dispens-
able for survival and reproduction. Approximately 20% of human
haplotypes carry a full deletion of the KLRC2/NKG2C gene
(hereafter referred to as NKG2C only) (Miyashita et al., 2004;
Moraru et al., 2012b; Thomas et al., 2012). Accordingly, approx-
imately 4% of the human population completely lacks the
NKG2C gene (NKG2C/). Although lack of NKG2C has been
linked to an increased risk of HIV progression (Thomas et al.,
2012), it is not overrepresented in children with severe
congenital HCMV infection (Noyola et al., 2012), and HCMV
seropositive NKG2C/ adults remain healthy without specific
symptoms. The lack of a clinical phenotype raises the question
of whether adaptive NK cell responses are physiologically rele-
vant or if other cellular mechanisms compensate for the loss of
NKG2C-driven adaptive NK cell responses. Here, comparative
studies of HCMV immunity in large cohorts of NKG2C-sufficient
and -deficient individuals revealed an unexpected redundancy in
the adaptive NK cell response and point to a critical role for CD2
in providing co-stimulation for NKG2C- and antibody-mediated
triggering of adaptive NK cells.
RESULTS
Minimal Imprint in T Cell Immunity in Individuals
Carrying Homozygous Deletion of NKG2C
The absence of more severe HCMV infection in NKG2C/
donors indicates the existence of redundant pathways forCellthe control of the infection. To enable
a comprehensive analysis of the im-
mune system in NKG2C/ donors, we
screened 2,208 healthy blood donorsand identified 81 NKG2C/ donors, corresponding to a fre-
quency of 3.7% in the Swedish population, in line with fre-
quencies reported in other populations (Miyashita et al., 2004;
Moraru et al., 2012b; Thomas et al., 2012).We then prospectively
obtained buffy coats from 60 of these for downstream analyses.
The demographics of the NKG2C/ cohort and of the age-
matched NKG2C+ controls (NKG2C+/ and NKG2C+/+) are sum-
marized in Table S1.
We analyzed the impact of homozygous NKG2C deletion on
the differentiation profile and the anti-HCMV response of CD4
and CD8 T cells from NKG2C/ donors as compared to
NKG2C+ (NKG2C+/+ or NKG2C+/) donors (Figures 1, S1, and
S2). We found that the NKG2C deletion resulted in a slight
but statistically significant accumulation of terminally differenti-
ated effector memory CD45RA+ (CCR7–CD45RA+) cells in the
CD8+ T cell compartment (24.1 ± 14.4 versus 32.3 ± 16.9,
p = 0.014), whereas no significant changes were observed for
any of the other CD8 T cell subsets studied (Figures S1A and
S1B). Interestingly, the accumulation of mature CD8 T cells
was particularly visible in young and middle-age individuals
(17.8 ± 9.6 versus 32.07 ± 17.2, p = 0.001; Figures 1A–1C). How-
ever, CD8 T cell responses following stimulation with overlap-
ping peptide pools derived from the HCMV proteins IE-1, IE-2,
and pp65 were identical in NKG2C/ and NKG2C+ individuals,
regardless of age (Figures 1D, S1C, and S1D). These results
were confirmed by using HLA-A*02 and HLA-B*07 tetramers
refolded with pp65-derived immunodominant peptides to
detect HCMV-specific CD8 T cells (Figures 1E, S1E, and S1F).
Similarly, NKG2C deletion was not associated with any signifi-
cant phenotypic or functional differences in CD4+ T cells (Fig-
ure S2) and did not imprint B cell differentiation (Figure S3).
Thus, despite an accumulation of terminally differentiated CD8
T cells in young NKG2C/ individuals, our results show that
no major reshaping of T and B cell immunity to HCMV takes
place in NKG2C-deficient individuals.Reports 15, 1088–1099, May 3, 2016 1089
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Figure 2. Redundant Adaptive NK Cell Response against HCMV in NKG2C/ Donors
(A and B) Unbiased bulk analysis of five HCMV–, five HCMV+NKG2C+/+, and five HCMV+NKG2C/ donors using the t-SNE algorithm. (A) Density plots show the
clustering of cell phenotypes in donors with and without adaptive NK cell populations stratified based on CMC seropositivity and presence/absence of the
NKG2C gene. (B) Differentiation marker distribution in the clusters defined for HCMV– (top), HCMV+NKG2C+/+ (middle), and HCMV+NKG2C/ donors (bottom).
Color codes indicate the expression intensity from the lowest (blue) to the highest (red).
(C) Representative fluorescence-activated cell sorting (FACS) plots of donors with (donor #02) and without (donor #01) evidence of NK cell adaptive response as
revealed by the upregulation of CD57, LILRB1, and downregulation of CD7, CD161, and FcεR1g.
(D) Frequency of HCMV+NKG2C+ and HCMV+NKG2C/ donors with a NK cell expansion.Adaptive NK Cell Response to HCMV in NKG2C/
Individuals
We recently reported that, among HCMV+ individuals, some dis-
played an expansion of NKG2C-negative NK cells, all of which
expressed activating KIRs (Be´ziat et al., 2013). Such adaptive
NK cells were identified by their highly differentiated phenotype,
manifested by reduced expression of CD7, CD161, and FcεR1g
and higher expression of CD57 and LILRB1 (Be´ziat et al., 2013,
2014; Zhang et al., 2013). To examine the possible existence
of adaptive NK cells in NKG2C/ donors, we analyzed multi-
parametric flow cytometry data by non-linear dimensionality1090 Cell Reports 15, 1088–1099, May 3, 2016reduction using t-distributed stochastic neighbor embedding
(t-SNE) (Figure 2A) (Amir et al., 2013). The t-SNE algorithm clus-
ters cells according to their expression of multiple parameters
and visualizes high-dimensional data in two-dimensional repre-
sentations, avoiding the bias introduced by manual gating of
specific subsets. This analysis clearly revealed clusters of cells
sharing the phenotypic hallmarks of adaptive NK cells in
NKG2C/ donors (Figures 2A and 2B). In fact, NKG2C was
the only marker that distinguished adaptive NK cell clusters in
NKG2C-sufficient and -deficient donors. Applying stringent
phenotypic criteria to assign a given cell population as adaptive,
we quantified the frequency of NKG2C+ and NKG2C/ donors
with imprints of adaptive NK cell responses (Figures 2C and
2D). Donors considered as carrier of an adaptive NK cell subset
were defined on the basis of significant expansion of cells,
representing >10% of CD56dim NK cells, displaying at least
four of the five phenotype characteristics (low CD7, low
CD161, low FcεR1g, high CD57, or high LILRB1). Among the
47 HCMV+NKG2C+ individuals in the control cohort, 16 (34%)
had a population of adaptive NK cells, in agreement with the
38% reported previously (Be´ziat et al., 2013). Surprisingly, we
found that 11 (25%) of the 44 HCMV+NKG2C/ donors had a
significant population (>10%) of adaptive NK cells, a proportion
not significantly different from the NKG2C+ individuals (Fisher’s
exact t test: p = 0.27) (Figure 2D). Notably, none of the 14
NKG2C+ or 16 NKG2C/ HCMV seronegative donors harbored
such expansions (data not shown), suggesting that, likeNKG2C+
donors, the expansions observed in NKG2C/ individuals were
related to HCMV infection.
Adaptive NKG2C/NKCells Preferentially Express Self
HLA-Specific KIR and Share Functional Attributes with
NKG2C+ Adaptive NK Cells
To further characterize the adaptive NK cell population in
NKG2C/ donors, we assessed their KIR repertoires. Strikingly,
as inNKG2C+ donors (Be´ziat et al., 2012, 2013), adaptive NK cell
populations in NKG2C/ donors displayed profound deviations
in their KIR repertoires (Figures 3A and S4) with preferential
expression of self-KIR and low frequencies of NKG2A (Figures
3B and 3C). More importantly, they shared functional attributes
of adaptive NK cells observed in NKG2C+ individuals. First,
they had a poor ability to produce interferon (IFN)-g after inter-
leukin-12 (IL-12)/IL-18 stimulation (Figure 3D). Second, they
displayed decreased degranulation capacity, measured via
cell-surface expression of CD107a, upon direct interaction with
K562 (p = 0.0046) and RAJI (p = 0.0005) cells and displayed
enhanced IFN-g (p < 0.0001) and tumor necrosis factor (TNF)
(p = 0.0002) production against antibody-coated target cells
compared to conventional NK cells (Figures 3E–3G). Third, in
line with the enhanced ability to produce IFN-g, compared to
conventional NK cells, they displayed a clear epigenetic remod-
eling associated with demethylation of CpG motifs in the
conserved noncoding sequence (CNS) 1 of the IFNG locus (Fig-
ure 3H), which was shown to be exclusively demethylated
in NKG2C-expressing expansions from HCMV+ individuals
(Luetke-Eversloh et al., 2014).
Altogether, these data demonstrate that NKG2C/ individ-
uals develop HCMV-driven adaptive NK cell responses at similar
frequencies and with similar epigenetic, phenotypic, and func-
tional properties as NKG2C+ individuals.
Adaptive Response to HCMV Occurs Independently of
Activating KIRs in NKG2C/ Individuals
The identification of adaptive NK cells in donors lacking NKG2C
raised the question of which potential activating receptors might
contribute to the expansion of this subset. Among other genes,
the NK gene complex on chromosome 12 encodes NKG2E, an
activating receptor that also forms functional heterodimers
with CD94 and recognizes HLA-E (Lanier et al., 1998; Lazeticet al., 1996). Since CD94 was at least weakly expressed on all
NK cells in both NKG2C+ and NKG2C/ donors (Figure 4A),
we asked whether an alternative activating CD94/NKG2 hetero-
dimer was functional on adaptive NK cells in the absence of
NKG2C. To this end, we stimulated NK cells with 221.AEH cells
or with P815 target cells coated with anti-CD94 (Figures 4B–4D).
These experiments demonstrated that neither triggering of CD94
(P815 + anti-CD94) nor stimulation with the natural HLA-E ligand
(221.AEH) induced functional responses in adaptive NK cells
from NKG2C/ donors when compared with NKG2C-express-
ing adaptive NK cells. These results exclude the involvement of
NKG2E in the expansion of adaptive NK cell subsets in
NKG2C/ donors.
Previous reports suggest that activating KIRs may compen-
sate for the loss of NKG2C in donors with a homozygous
NKG2C deletion (Be´ziat et al., 2013; Della Chiesa et al., 2014).
Accordingly, we examined the relative contribution of NKG2C
and activating KIRs to the adaptive NK cell pool in each donor
(Figure 4E). In NKG2C+ donors, 60% of the expansions ex-
pressed only NKG2C, 27% co-expressed NKG2C and an acti-
vating KIR (KIR2DS1, KIR2DS2, KIR3DS1, or KIR2DS4), whereas
13% of the expansions expressed predominantly an activating
KIR. Surprisingly, we found similar overall frequencies of acti-
vating KIR-positive expansions in NKG2C/ individuals (36%)
(Figure 4E). Moreover, the magnitude of the adaptive response,
determined as the fraction of adaptive NK cells within the total
NK cell subset, did not differ in donors with and without the
NKG2C deletion and seemed to be independent of the activating
receptor composition (Figure 4F). Although our phenotypic anal-
ysis did not include KIR2DS3 and KIR2DS5, the detection of
three haplotype A/A donors among the 11 NKG2C/ donors
with an expansion allowed us to conclude that the expression
of NKG2C and/or activating KIRs are not prerequisites for the
emergence of adaptive NK cells.
CD2 and CD16 Synergistically Activate Adaptive NK
Cells
The finding that adaptive NK cell responses can occur indepen-
dently of NKG2C and activating KIRs prompted us to revisit the
potential role of other activating receptors expressed by NK
cells. We found a profound downregulation of NKp46, stable
expression or weak downregulation of 2B4, NTB-A, CRACC,
and NKG2D and an increased expression of DNAM-1 and CD2
in adaptive NK cells of both NKG2C/ and NKG2C+ donors
(Figures 5A, 5B, and S5A). Next, we addressed whether any
particular activating receptors could co-stimulate human adap-
tive NK cells in a fashion similar to that described for DNAM-1
in Ly49H-driven responses in the mouse (Nabekura et al.,
2014). Since it was recently shown that antibody-mediated
recognition of CMV-infected cells can drive the expansion of
adaptive NK cells (Lee et al., 2015), we tested the ability of
CD2 (Figures 5C and S5B), 2B4, and DNAM-1 (Figure S5C) to
co-stimulate the CD16 pathway in adaptive NK cells from both
NKG2C/ and NKG2C+ donors. Agonistic stimulation of CD2
and CD16 using antibody-coated P815 cells revealed a striking
synergistic interaction between CD2 and CD16 that was not
observed for any other receptor combinations or in conventional
NK cells. Thus, ligation of CD16 together with CD2 led to anCell Reports 15, 1088–1099, May 3, 2016 1091
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Figure 3. Adaptive NK Cells in NKG2C/ Donors Share Most Attributes of NKG2C-Expressing Adaptive NK Cells
(A) NKG2A and KIR repertoire in conventional (left column) and adaptive (right column) NK cells of NKG2C/ donors.
(B and C) Frequency of NKG2A+ NK cells (B) and educated cells (C) in adaptive and conventional NK cells of NKG2C+ and NKG2C/ donors.
(D) Representative intracellular IFN-g production by conventional and adaptive NK cells in NKG2C+ (n = 16) and NKG2C/ (n = 11) donors after overnight
stimulation with IL-12 and IL-18.
(E–G) Functional assay of conventional CD56dim NK cells as compared to adaptive NK cells from HCMV+NKG2C+ (n = 16) or HCMV+NKG2C/ (n = 11) donors.
Cell-surface expression of CD107a (E) and intracellular expression of TNF (F) and IFN-g. (G) were assessed after 6 hr of stimulation with K562 target cells or RAJI
target cells in the presence of anti-CD20 (rituximab, 1 mg/ml).
(H) CpGmethylation profile relative to transcriptional start site (TSS) of the IFN-g promoter in adaptive NK cells compared to NKG2A– andNKG2A+CD57– subsets.
Four NKG2C/ and six NKG2C+/+ donors were analyzed. The error bars represent the SEM.
1092 Cell Reports 15, 1088–1099, May 3, 2016
A
E
F
B
C
D
Figure 4. Adaptive Responses of NK Cells
in NKG2C/ Individuals Independently of
CD94 and Activating KIRs
(A) CD94 expression by the NKG2A+ (blue lines),
the NKG2A–NKG2C– (black dotted lines), and the
adaptive (red lines) subsets of HCMV+NKG2C+
(left) and HCMV+NKG2C/ (right) donors as
compared to a fluorescence minus one (FMO)
control.
(B–D) Functional assay of conventional CD56dim
NK cells as compared to adaptive NK cells from
HCMV+NKG2C+ (n = 16) or HCMV+NKG2C/
donors (n = 11). Cell-surface expression of
CD107a (B) and intracellular expression of TNF
(C) and IFN-g (D) were assessed after 6 hr of
stimulation with target cells expressing HLA-E
(221.AEH) or not (721.221) or redirected stimula-
tion with P815 and mouse anti human CD94
(10 mg/ml) or an isotype control. Error bars repre-
sent the SEM. (B–D) Adaptive subsets in
NKG2C+/+ and NKG2C/ donors were defined by
the FcεR1g–CD57+ phenotype.
(E) Frequency of NKG2C+ and NKG2C/ donors
having the indicated phenotype as their domi-
nating (>50%) adaptive subset.
(F) Size of the adaptive NK cell subset in NKG2C+
and NKG2C/ donors. Three haplotype A/A do-
nors are marked with an A at the top of their
respective columns.increase in IFN-g and TNF-producing cells compared to CD16
stimulation alone (Figures 5C and S5B). Titrating the dose of
CD16 revealed that CD2 engagement enhanced the maximum
response compared to CD16 crosslinking alone without influ-
encing the response threshold (Figure 5D).
Next, we explored the potential contribution of CD2 to anti-
body-triggered responses by adaptive and conventional NK
cells. To this end, we made use of the CD20+ RAJI B cell
lymphoma line, which expresses CD58, the ligand of CD2. We
monitored functional responses in the two subsets following in-
cubation with anti-CD20 (rituximab)-coated RAJI cells. CD2
blockade led to a profound decrease of IFN-g and TNF produc-
tion aswell as degranulation (Figure 5E). The costimulatory effect
of CD2 was evident at low rituximab concentrations, suggesting
that this pathway may boost the CD16 responses in the context
of low levels of immunoglobulins. The blocking of CD2 also re-
vealed a modest but significant synergy between CD2 and
CD16 in conventional NK cells for IFN-g and TNF production
(Figure 5E). Notably, blockade of CD2 abrogated the difference
in functional responses between adaptive and conventional NK
cell subsets, suggesting that CD2 co-stimulation is a crucial
element of the enhanced antibody-dependent responses by
adaptive NK cells.
In NKG2C+ donors, NKG2C has a unique ability, alongside
CD16, to trigger functional responses in resting NK cells without
the need for additional co-activation (Luetke-Eversloh et al.,
2014). Therefore, we tested the potential synergy between
CD2, CD16, and NKG2C in the NKG2C-expressing subset
from HCMV– (conventional phenotype) and HCMV+ (adaptive
phenotype) donors. Functional assays with agonistic mono-clonal antibodies (mAbs) revealed synergies between NKG2C
and CD2 in adaptive NK cells of HCMV+ individuals but not in
conventional NK cells (Figure 5F). Blockade of CD2 interactions
with its natural ligand in target cell assays with HLA-E-express-
ing 221 cells had a broader effect and diminished the response
in both conventional and adaptive NK cells (Figure 5G), poten-
tially attributed to an additional effect on target cell adhesion
(Hahn and Bierer, 1993). Together these results reveal a unique
role for CD2 in specifically boosting functional responses medi-
ated through CD16 and NKG2C in adaptive NK cells.
CD2Co-stimulation Boosts the CD16 Signaling Cascade
To dissect the mechanism underlying CD2 costimulation in
adaptive NK cells, we monitored the phosphorylation kinetics
of key signaling molecules downstream of CD16, including
CD3-z, ZAP70/Syk, SLP76, LAT, ERK1/2 (MAP kinase pathway),
and S6RP (mTORC pathway), using phosphoflow cytometry
(Figures 6A–6D) (Long et al., 2013). Unlike T cells (Kaizuka
et al., 2009), no signaling events was induced in conventional
or adaptive NK cells when triggered with anti-CD2 alone (Figures
6B–6D). In contrast, CD16 crosslinking induced phosphorylation
of all signaling molecules tested in both NK subsets. In line with
the functional readouts, CD16-induced phosphorylation of
SLP76, ERK1/2, and S6RP was stronger in adaptive compared
to conventional NK cells (Figure 6D). In conventional NK cells,
we noted a weak synergy between CD2 and CD16 that was sig-
nificant for the phosphorylation of ERK1/2 after 1min (mean ratio
1.6 versus 1.9, p = 0.0006) and S6RP after 10min (mean ratio 6.6
versus 10.3, p < 0.0001). In adaptive NK cells, however, co-liga-
tion of CD2 and CD16 led to significantly higher levels ofCell Reports 15, 1088–1099, May 3, 2016 1093
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Figure 5. Synergistic Effect of CD2 and CD16 in Adaptive NK Cells
(A and B) Representative FACS (A) plot and summary graph (B) of CD2 expression in adaptive NK cells of NKG2C+ and NKG2C/ donors.
(C) Functional assay of conventional (white) CD56dim NK cells as compared to adaptive (red) NK cells from NKG2C/ (n = 10) donors. Cell-surface expression of
CD107a and intracellular expression of TNF and IFN-g were assessed after 6 hr of redirected stimulation with P815 using mouse anti-human antibodies, as
indicated (5 mg/ml).
(D) Cell-surface expression of CD107a and intracellular expression of TNF and IFN-g production in conventional (black lines) versus adaptive (red lines) NK cells of
five NKG2C/ donors after 6 hr of redirected stimulation with P815 cells and anti-CD16 alone (closed symbols) or anti-CD2 (5 mg/ml) together with anti-CD16
(open symbols) at indicated concentrations. Significant differences of adaptive NK cell responses after CD16 stimulation compared to CD16+CD2 stimulation are
depicted.
(E) Cell-surface expression of CD107a and intracellular expression of TNF and IFN-g production in conventional (black lines) versus adaptive (red lines) NK cells of
five NKG2C/ donors after 6 hr of stimulation with RAJI cells coated with the indicated concentration of anti-CD20 (rituximab) in presence (close symbols) or
absence (open symbols) of CD2 blocking. Significant differences of adaptive (red stars) and conventional (black stars) NK cell responses after rituximab stim-
ulation with or without CD2 blocking are depicted.
(C–E) Adaptive subsets in NKG2C/ donors were defined by the FcεR1g–CD57+ phenotype.
(legend continued on next page)
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phosphorylation of all signaling molecules. This synergistic in-
duction of signaling in adaptive NK cells was particularly pro-
nounced for ERK1/2 after 5 min (mean ratio 2.9 versus 3.9,
p = 0.017) and S6RP after 10 min (mean ratio 25.5 versus 39.8,
p = 0.0066). Taken together, these results demonstrate that
the costimulation of CD16 by CD2 is mechanistically linked
to the synergistic induction of the MAP kinase and mTORC
pathways.
DISCUSSION
During the last decade, it has become clear that NK cells
possess the ability to calibrate their functional potential and
respond to pathogenic challenges in a fashion that is commonly
attributable to cells within the adaptive immune system. How-
ever, the natural drivers behind these responses remain largely
unknown. In the mouse, the activating receptor Ly49H has prob-
ably evolved to counteract the decoy major histocompatibility
complex (MHC) class I molecule in MCMV, m157, which allows
the virus to escape NK cells expressing the inhibitory receptor
Ly49C (Forbes et al., 2014; Pyzik et al., 2014). However, Ly49H
is not found in all mouse strains suggesting that it is not required
for survival in natura, despite the protection it confers against
MCMV in certain laboratory strains (Arase et al., 2002). In the hu-
man, the activating NKG2C receptor is expressed by a majority
of adaptive NK cells responding to HCMV. However, individuals
lacking this receptor are perfectly healthy and appear fully
capable of controlling HCMV infection. Thus, the immunological
control of both mouse and human CMV must involve other acti-
vating NK cell receptors, compensatory immune responses by
other lymphocyte subsets or a combination thereof. The com-
parison of NK cell repertoires in two large cohorts of healthy do-
nors either lacking or expressing the NKG2C gene allowed us to
address these possibilities in the human.
Here, adaptive NK cell responses in NKG2C/ individuals
were limited to CMV-seropositive donors and occurred at similar
frequencies as the previously described adaptive NK cell expan-
sions in NKG2C+ donors. Although these expansions shared
phenotypic, epigenetic, and functional attributes with NKG2C-
expressing expansions, most of the identified NK cell popula-
tions lacked all known drivers of adaptive NK cell responses,
including activating KIRs (Be´ziat et al., 2013; Della Chiesa
et al., 2014). The question raised, then, is which other activating
signals may be involved in driving adaptive NK cell responses in
NKG2C/ donors. To address this, we first excluded the
involvement of CD94/NKG2E by confirming that CD94 triggering
and stimulation with HLA-E+ targets failed to activate NKG2C
adaptive NK cells. This outcome is in accordance with the results
of Orbelyan et al., showing that NKG2E is retained within the
endoplasmic reticulum due to hydrophobic amino acids in the
extracellular domain of the protein (Orbelyan et al., 2014).
A broad profiling of activating receptor expression on adaptive
NK cells from NKG2C/ donors, we noted increased levels of(F) Intracellular IFN-g production in the NKG2C+ subset of CMV+ (red, n = 5) and
indicated combination of mouse anti-human CD2, CD16, and NKG2C antibodies
(G) Intracellular IFN-g production in the NKG2C+ subset of CMV+ (red, n = 8) and C
(221.AEH) or not (221) HLA-E. Error bars represent the SEM.DNAM-1 and CD2, two receptors that synergize with NKp46 to
trigger resting NK cells (Bryceson et al., 2006). DNAM-1 expres-
sion is enhanced in educated NK cells and cooperates with
LFA-1 to form stable target cell conjugates (Enqvist et al.,
2015). In mice, DNAM-1 marks NK cell maturation (Martinet
et al., 2015) and was found to be critical for the expansion of
Ly49H+ NK cells after MCMV infection (Nabekura et al., 2014).
Although our results do not exclude the involvement of
DMAM-1 in the early phase of adaptive NK cell expansion and
differentiation in the human, we did not observe costimulatory
potential of this receptor in adaptive NK cells. Therefore, we
turned our attention to CD2. CD2 is amajor coactivating receptor
expressed on NK and T cell subsets (Davis and van der Merwe,
1996); it recognizes CD58, a ligand expressed on a wide variety
of tissues (Smith and Thomas, 1990). In resting conventional NK
cells, cross-linking of CD2 with NKp46 increases the intracellular
calcium flux, but not cytokine production or degranulation (Bry-
ceson et al., 2006). Extending these results, we here describe a
potent synergy between CD2 and CD16 that is unique to adap-
tive NK cells. Furthermore, CD2 ligation co-stimulated NKG2C-
mediated responses in adaptive NK cells from NKG2C+ donors,
suggesting that CD2 plays a broad role in the functionality of
adaptive NK cells.
Notably, patients with homozygous missense mutations in
CD16 have poor natural cytotoxicity, which is attributable to
the loss of physical interactions between CD16 and CD2 (Grier
et al., 2012). CD16 stabilizes the expression of CD2 and the
two molecules co-localize at the immune synapse allowing
CD2 to tap into the signaling pathway downstream of CD16.
CD16 and NKG2C are associated with dimers of immunorecep-
tor tyrosine-based activation motif (ITAM)-containing molecules,
FcεR1g and/or CD3-z for CD16 and DAP12 for NKG2C (Lanier,
2008). CD3-z and DAP12 are expressed in all NK cells, while
FcεR1g is often downregulated in adaptive NK cells (Lee et al.,
2015; Schlums et al., 2015; Zhang et al., 2013). As a conse-
quence, in adaptive NK cells, CD16 is mostly associated with
CD3-z/CD3-z homodimers (eight ITAMs) instead of CD3-z/
FcεR1g (six ITAMs) or FcεR1g/FcεR1g (four ITAMs) dimers.
Since CD2 signaling was shown to be dependent on CD3-z
(Moingeon et al., 1992; Vivier et al., 1991), it is tempting to spec-
ulate that this quantitative difference in ITAMmotif contributes to
the enhanced CD16 responses in adaptive NK cells. Supporting
this notion, our data show that CD2 co-activation of CD16 in
adaptive FcεR1g– NK cells leads to an increase phosphorylation
of CD3-z aswell as of all the other signalingmolecules we tested.
However, only a fraction of adaptive NK cells are FcεR1g–
(Schlums et al., 2015), and NKG2C+FcεR1g+ adaptive NK cells
also exhibited heightened responses to CD2 and CD16 costimu-
lation (data not shown), suggesting that alternative signaling
pathways may be involved.
Adaptive NK cells displayed enhanced phosphorylation of
ERK and S6RP upon CD16 and CD2 co-activation. ERK is a
major hub of signal transduction in the MAP-kinase pathway,CMV– (blue, n = 5) donors after 6 hr of redirected stimulation with P815 and
(5 mg/ml each).
MV– (blue, n = 8) donors after 6 hr of stimulation with 721.221 cells expressing
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Figure 6. CD2 Co-activates the CD16-Induced Signaling Pathway in Adaptive NK Cells
(A) Barcoding and gating strategy used to identify adaptive and conventional NK cells in the phosphoflow cytometry analysis.
(B–D) Phosphorylation of the indicated phospho-epitopes in adaptive or conventional NK cells after CD2 and/or CD16 crosslinking. (B) Representative histogram
plots at the indicated stimulation time point. (C and D) Mean fluorescence intensity (MFI) fold change of the indicated phospho-epitopes in conventional subset
(solid line) of four HCMV– (C) and the conventional (solid line) or adaptive (dotted line) subsets of four HCMV+ (D) individuals. Among the four HCMV+ donors, three
were NKG2C+ and one was NKG2C/.
Error bars represent the SEM.whereas S6RP is downstreamof themTORC1 complex; both are
late signaling events involved in numerous central processes in
lymphocytes, including proliferation, differentiation, and cyto-
kine production (Dong et al., 2002; Pollizzi and Powell, 2014).1096 Cell Reports 15, 1088–1099, May 3, 2016Recently, mTORC pathway activity was shown to be essential
for mouse NK cell development (Marc¸ais et al., 2014). Our results
suggest that this pathway should also be scrutinized for its po-
tential role in the development of adaptive NK cell responses.
The signaling cascade integrates different signals and functions
as a signal amplifier. Therefore, an initially relatively small differ-
ence can get larger further down in the cascade. This fit with the
gradually increasing differences observed in the present study:
p-CD3z/p-ZAP70 < p-SLP76 < p-Erk. Indeed, we observed a
tendency for increased phosphorylation of all proximal readouts
following CD2 and CD16 costimulation of adaptive NK cells.
Thus, although a major difference of phosphorylation can be
excluded for these early signaling events, more subtle variations
might remain unseen due to a lack of sensitivity.
Given the synergy observed between NKG2C and CD2, it is
plausible that CD2 can also cooperate with other DAP12-
coupled receptors such as activating KIRs, although this possi-
bility was not specifically examined here. It will be of interest to
explore whether CD2 costimulation of CD16-driven responses
influence the functional reprogramming of the cell during expan-
sion in a fashion similar to that noted in the context of T cell
exhaustion in autoimmunity and infection (McKinney et al.,
2015).
The expansion of adaptive NK cells in the absence of acti-
vating KIRs and NKG2C suggests that a combination of other
NK receptors and or external factors contribute to elicit such re-
sponses. In this context, antibody-mediated recognition of viral
antigens as a driver of adaptive NK cell responses is particularly
appealing (Lee et al., 2015). Since CD2 is expressed at high
levels on all adaptive NK cell subsets and significantly boost
the response of NK cells to CD16 ligation, it is conceivable that
recognition of CD58 on HCMV-infected cells play a role in
shaping adaptive NK cell responses. HCMV has tropism for
epithelial cells, endothelial cells, myeloid cells, and fibroblasts,
all of which express CD58 (Revello andGerna, 2010). CMV infec-
tion also causes loss of HLA class I (Tandon and Mocarski,
2012). Thus, CMV-infected cells fulfill all criteria for efficiently
stimulating self-KIR+ adaptive NK cells via CD2 and CD16.
Outstanding remaining questions are to define the cellular inter-
actions that trigger the onset of adaptive NK cell responses as
well as the cellular entities that maintain stable repertoires for
many years during latency. Our results point to the necessity of
looking beyond NKG2C and consider the possibility that broadly
expressed receptors, such as CD2, provide essential co-stimu-
latory signals to NK cells, corresponding to signal 2 in the gener-
ation of adaptive T cell responses (Smith-Garvin et al., 2009).
Another major purpose of the current study was to examine
whether the loss of NKG2C-driven responses had any influence
on T cell-mediated immunity to HCMV. NKG2C/ donors dis-
played similar frequencies of CMV-specific T cells as the
NKG2C+ donors, suggesting that lack of NKG2C had no major
impact on the T cell response to the virus. However, we observed
an accumulation of effector memory CD45RA+ CD8 T cells
earlier in life in HCMV+NKG2C/ individuals, potentially indi-
cating a stronger CD8 T cell response in the early phase of
HCMV infection in the absence of NKG2C-driven adaptive NK
cell immunity. This notion is supported by an extensive study
of a rural population of Gambia, a country with almost universal
HCMV seroprevalence; i.e., almost 100% of the population was
HCMV+ by 6 years of age (Goodier et al., 2014). Although specific
T cell immunity was not analyzed, immunoglobulin G (IgG) titers
against HCMV were elevated in young individuals lacking theNKG2C gene. These results suggest that, despite a high level
of redundancy within the NK cell compartment itself, the lack
of NKG2C might also be partly compensated for by enhanced
T and B cell responses, particularly during the early phases of
HCMV infection. Possibly, an effective adaptive NK cell immunity
helps to control the burden of HCMV infection before the emer-
gence of efficient T and B cell immunity. Although adaptive
NK cells displayed reduced degranulation responses, their
enhanced ability to release cytokines in response to antibody-
coated targets might help to fulfill this role and contribute to
maintaining the virus silent during latency. The plasticity of adap-
tive NK cell responses in the absence of activating KIRs and
NKG2C points to the importance of such responses within the
innate immune system.
EXPERIMENTAL PROCEDURES
Human Participants and Cells
This study was conducted in accordance with the Declaration of Helsinki
and was approved by the ethics committee in Stockholm, Sweden. 2,208
random healthy blood donors were screened for NKG2C expression by flow
cytometry. Donors lacking NKG2C expression were confirmed by PCR using
the protocol described by Moraru et al. verifying homozygous deletion of
NKG2C gene (Moraru et al., 2012a). 60 controls expressing NKG2C and 60
donors lacking the NKG2C gene were identified and enrolled in the study.
For all donors, peripheral blood mononuclear cells (PBMCs) were cryopre-
served for later use. Genomic DNA was isolated using the DNeasy Blood
and Tissue Kit (QIAGEN).
KIR and KIR-Ligand Typing and HCMV Serology
KIR ligands were determined using the KIR HLA ligand kit (Olerup SSP;
QIAGEN) for detection of the HLA-Bw4, HLA-C1, and HLA-C2 motifs. KIR
genotyping was performed by using quantitative KIR automated typing
(qKAT) (Jiang et al., 2012). HCMV serology was determined using an ELISA-
based assay on plasma obtained during sample preparation. Purified nuclear
CMV antigen (AD 169) was used, and the cut-off level for seropositivity was an
absorbance ofR0.2 at a dilution of 1/100.
Flow Cytometry
A list of fluorochrome-conjugated reagents used for stainings can be found in
the Supplemental Experimental Procedures. Detailed protocols of flow cytom-
etry staining, Stochastic neighbor embedding (SNE) analysis, functional flow
cytometry assays, including T and NK cell functional assays and phospho
flow cytometry experiments, are provided in the Supplemental Experimental
Procedures. KIR repertoire analyses were performed according to the strategy
previously described (Be´ziat et al., 2014).
DNA Methylation Analysis
DNA methylation was analyzed as previously described (Luetke-Eversloh
et al., 2014). The methylation levels of six CpG residues within the IFNG
CNS1 region were analyzed via bisulfite conversion and pyrosequencing by
Varionostic. Donors were selected based on the size of the three target sub-
sets to ensure sufficient numbers of cells for methylation analysis after sorting.
Statistics
For multiple group comparisons, one-way ANOVA, two-way ANOVA, or Krus-
kal Wallis nonparametric tests were applied. For single comparisons of inde-
pendent groups, the Student’s t test or theMann-Whitney test was performed.
For single comparisons of matched groups, the paired Student’s t test or the
Wilcoxon matched pairs test was performed depending on the sample size
and distribution. For comparisons of qualitative variable, the Fisher’s exact
t test was performed. In the relevant figures, n.s. indicates not significant;
***p < 0.001; **p < 0.01; and *p < 0.05. Analyses were performed using
GraphPad software.Cell Reports 15, 1088–1099, May 3, 2016 1097
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